TY - JOUR
T1 - Genetics of diffuse large b-cell lymphoma
T2 - Paving a path to personalized medicine
AU - King, Rebecca L.
AU - Bagg, Adam
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Diffuse large B-cell lymphoma, the most common type of lymphoma in Western countries, remains incurable in approximately 40% of patients. Over the past decade, nascent molecular technologies have led to the discovery of many of the genetic events underlying the pathogenesis of this group of diseases. Whether by defining gene signatures that subclassify diffuse large B-cell lymphoma into subgroups, dysregulation of key cellular pathways, or specific mutations, we are approaching an era in which personalized diagnostics, prognostication, and therapy are imminent.
AB - Diffuse large B-cell lymphoma, the most common type of lymphoma in Western countries, remains incurable in approximately 40% of patients. Over the past decade, nascent molecular technologies have led to the discovery of many of the genetic events underlying the pathogenesis of this group of diseases. Whether by defining gene signatures that subclassify diffuse large B-cell lymphoma into subgroups, dysregulation of key cellular pathways, or specific mutations, we are approaching an era in which personalized diagnostics, prognostication, and therapy are imminent.
KW - Diffuse large B-cell lymphoma
KW - nascent molecular technologies
KW - personalized diagnostics
UR - http://www.scopus.com/inward/record.url?scp=84893529346&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84893529346&partnerID=8YFLogxK
U2 - 10.1097/PPO.0000000000000014
DO - 10.1097/PPO.0000000000000014
M3 - Review article
C2 - 24445764
AN - SCOPUS:84893529346
SN - 1528-9117
VL - 20
SP - 43
EP - 47
JO - Cancer Journal (United States)
JF - Cancer Journal (United States)
IS - 1
ER -